Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Exclusion Criteria

• •1. Patients with another malignant disease.
• •2. Patients has participated in or participating in other clinical trials.
• •3. Patients with uncontrolled active infection.
• •4. Patients with left ventricular ejection fraction \< 0.5 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification.
• •5. Patients with aspartate aminotransferase or glutamic-pyruvic transaminase \> 3x upper limit of normal or bilirubin \> 2.0 mg/dL.
• •6. Patients with creatinine clearance rate \< 50ml/min.
• •7. Patients with active hepatitis B or hepatitis C infection.
• •8. Patients with HIV infection.
• •9. Patients with active tuberculosis infection.
• •10. Patients with uncontrolled active bleeding.
• •11. Patients with a history of allergy to experimental drugs.
• •12. Patients with other commodities that the investigators considered not suitable for the enrollment.